Drugmakers go nuclear, continuing push into radiopharmaceuticals
Elie Dolgin • June 10, 2021
With late-stage trial success, venture funding and next-generation alpha emitters on the way, targeted radiotherapy drugs are finally “getting the attention they deserve.”
The clinical success of the first targeted radiopharmaceutical designed to combat a common type of cancer looks poised to help bring the once-fringe treatment modality into the medical mainstream.
Earlier this month, Novartis reported phase 3 data from its VISION trial showing that men with metastatic castration-resistant prostate cancer lived longer when, in addition to standard-of-care treatments, they received the company’s 177Lu-PSMA-617, a small-molecule drug that delivers radiation-emitting lutetium isotopes to cells expressing prostate-specific membrane antigen (PSMA).
Continue reading at Nature Biotechnology.
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.